The incidence and outcomes of pancreatectomy in patients with metastatic pancreatic adenocarcinoma

Journal of the Pancreas

Volumn 11, Issue 4, 2010, Pages 341-347

  McKenzie, Shaun ^a   Mailey, Brian ^a   Artinyan, Avo ^a   Kim, Joseph ^a   Ellenhorn, Joshua D I ^a  

^a CITY OF HOPE NATIONAL MEDICAL CENTER   (United States)

Author keywords

Carcinoma; Pancreatic ductal; Pancreatic neoplasms; Pancreaticoduodenectomy

Indexed keywords

ANTINEOPLASTIC AGENT;

ADULT; AGED; ARTICLE; CANCER ADJUVANT THERAPY; CANCER EPIDEMIOLOGY; CANCER MORTALITY; CANCER RADIOTHERAPY; CANCER STAGING; CANCER SURVIVAL; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; METASTASIS; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PANCREAS ADENOCARCINOMA; PANCREAS RESECTION; SURVIVAL TIME; TREATMENT PLANNING; TREATMENT RESPONSE; TUMOR BIOPSY; ADENOCARCINOMA; EVALUATION STUDY; INCIDENCE; MIDDLE AGED; PANCREATIC NEOPLASMS; PATHOLOGY; PROGNOSIS; STATISTICS AND NUMERICAL DATA; TREATMENT OUTCOME; VERY ELDERLY; YOUNG ADULT;

ADENOCARCINOMA; ADULT; AGED; AGED, 80 AND OVER; FEMALE; HUMANS; INCIDENCE; MALE; MIDDLE AGED; NEOPLASM METASTASIS; PANCREATECTOMY; PANCREATIC NEOPLASMS; PROGNOSIS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 77954787546     PISSN: None     EISSN: 15908577     Source Type: Journal    
DOI: None     Document Type: Article

References (31)

1. Jemal A,Siegal R, Ward E, Hao Y, Xu J, Murray T, Thun M. Cancer Statistics 2008. CA Cancer J Clin 2008; 58:71-96. [PMID 18287387]
2. Nieto J, Grossbard M, Kozuch P. Metastatic pancreatic cancer 2008. Is the glass less empty? Oncologist 2008; 13:562-76. [PMID 18515741]
3. Neoptolemos J, Stocken D, Freiss H, Bassi C, Dunn J, Hickey H, et al. A randomized trial of chemoradiotherapy and chemotherapy after resection of pancreatic cancer. N Engl J Med 2004; 350:120010. [PMID 15028824]
4. Winter J, Cameron J, Campbell K, Arnold M, Chang D, Coleman J, et al. 1423 pancreaticoduodenectomies for pancreatic cancer: a single institution experience. J Gastrointest Surg 2006; 10:1199-210. [PMID 17114007]
5. Wagner M, Redaelli C, Lietz M, Seiler C, Friess H, Buchler MW. Curative resection is the single most important factor determining outcome in patients with pancreatic adenocarcinoma. Br J Surg 2004; 91:586-94. [PMID 15122610]
6. Shaib Y, Davila J, Naumann C, El-Serag H. The impact of curative intent surgery on the survival of pancreatic cancer patients: a U.S. population-based study. Am J Gastroenterol 2007; 102:1377-82. [PMID 17403071]
7. Takada T, Yasuda H, Amano H, Yoshida M, Uchida T. Simultaneous hepatic resection with pancreato-duodenectomy for metastatic pancreatic head carcinoma: does it improve survival? Hepatogastroenterology 1997; 44:567-73. [PMID 9164539]
8. Gleisner A, Assumpcao L, Cameron J, Wolfgang C, Choti M, Herman J, et al. Is resection of periampullary or pancreatic adenocarcinoma with synchronous hepatic metastasis justified? Cancer 2007; 110:2484-92. [PMID 17941009]
9. Shrikhande S, Kleeff J, Reiser C, Weitz J, Hinz U, Esposito I, et al. Pancreatic resection for M1 pancreatic ductal adenocarcinoma. Ann Surg Oncol 2006; 14:118-27. [PMID 17066229]
10. National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines™). Pancreatic Adenocarcinoma. V.I.2010. Fort Washington, PA, USA. (Accessed Oct 6, 2009).
11. National Cancer Institute. Pancreatic Cancer Treatment (PDQ®). Health Professional Version. Bethesda, MD, USA. (Accessed Oct 6, 2009).
12. Kim J, Mailey B, Senthil M, Artinyan A, Sun C, Bhatia S. Disparities in gastric cancer outcomes among Asian ethnicities in the USA. Ann Surg Oncol 2009; 16:2433-41. [PMID 19582508]
13. World Health Organization. ICD-O: International Classification of Diseases for Oncology, 3rd Ed. (ICD-O-3). Geneva, Switzerland: World Health Organization, 2000.
14. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958; 53:457-81.
15. Sener SF, Fremgen A, Menck HR, Winchester DP. Pancreatic cancer: a report of treatment and survival trends for 100,313 patients diagnosed from 1985-1995, using the National Cancer Database. J Am Coll Surg 1999; 189:1-7. [PMID 10401733]
16. Burris H, Moore M, Anderson J, Green M, Rothenburg M, Modiano M, et al. Improvements in survival and clinical benefit with Gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. J Clin Oncol 1997; 15:2403-13. [PMID 9196156]
17. Sultana A, Smith C Cunningham D, Starling N, Neoptolemos J, Ghaneh P. Meta-analyses of chemotherapy for locally advanced and metastatic pancreatic cancer. J Clin Oncol 2007; 25:2607-15. [PMID 17577041]
18. Yip D, Karapetis C, Strickland A, Steer C, Goldstein D. Chemotherapy and radiotherapy for inoperable advanced pancreatic cancer. Cochrane Database Syst Rev 2006; 3:CD002093. [PMID 16855985]
19. Heinemann V, Boeck, S Hinke A, Labianca R, Louvet C. Meta-analysis of randomized trials: evaluation of benefit from gemcitabine-based combination chemotherapy applied to advanced pancreatic cancer. BMC Cancer 2008; 8:82. [PMID 18373843]
20. Moore M, Goldstein D, Hamm J, Figer A, Hecht J, Gallinger S, et al. Erlotinib plus gemcitabine compared to gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 2007; 25:1960-6. [PMID 17452677]
21. Philip PA, Benedetti J, Fenoglio-Preiser C, Zalupski M, Lenz H, O'Reilly E, et al. Phase III study of gemcitabine plus cetuximab versus gemcitabine in patients with locally advanced or metastatic pancreatic adenocarcinoma SWOG S0205 study. J Clin Oncol 2007; 25(18 Suppl):LBA4509.
22. Kullmann F, Hollerbach S, Dollinger M, Harder J, Fuchs M, Messmann H, et al. Cetuximab plus gemcitabine/oxaliplatin (gemocet) in first-line metastatic pancreatic cancer: a multicentre phase II study. Br J Cancer 2009; 100:1032-6. [PMID 19293797]
23. Kindler HL, Niedzwiecki D, Hollis D, Oraefo E, Schrag D, Hurwitz H, et al. A double-blind, placebo-controlled, randomized phase III trial of gemcitabine plus bevacizumab versus gemcitabine plus placebo in patients with advanced pancreatic cancer: a preliminary analysis of Cancer and Leukemia Group B (CALGB) 80303. J Clin Oncol 2007; 25(18 Suppl):4508.
24. Saif M. New developments in the treatment of pancreatic cancer. Highlights from the '44th ASCO Annual Meeting'. Chicago, IL, USA. May 30 - June 3, 2008. JOP. J Pancreas (Online) 2008; 9:3917. [PMID 18648128]
25. Ko AH, Dito E, Schillinger B, Venook AP, Xu Z, Bergsland EK, et al. A phase II study evaluating bevacizumab in combination with fixed-dose rate gemcitabine and low-dose cisplatin for metastatic pancreatic cancer: is an anti-VEGF strategy still applicable? Invest New Drugs 2008; 26:463-71. [PMID 18379729]
26. Van Cutsem E, Vervenne W, Bennouna J Humblet Y, Gill S, Van Laethem J, et al. Phase III trial of bevacizumab in combination with gemacitabine and erlotinib in patients with metastatic pancreatic cancer. J Clin Oncol 2009; 27:2231-7. [PMID 19307500]
27. Schelldorfer T, Ware A, Sarr M, Smyrk T, Zhang L, Qin R, et al. Long-term survival after pancreatoduodenectomy for pancreatic adenocarcinoma: is cure possible? Ann Surg 2008; 247:456-62. [PMID 18376190]
28. Riall T, Cameron J, Lillemoe K, Winter J, Campbell, Hruban R, et al. Resected periampullary adenocarcinoma: 5-year survivors and their 6- to 10-year follow up. Surgery 2006; 140:764-72. [PMID 17084719]
29. Ferrone C, Brennan M, Gohen M, Coit D, Fong Y, Chung S, et al. Pancreatic adenocarcinoma: the actual 5-year survivors. J Gastrointest Surg 2008; 12:701-6. [PMID 18027062]
30. Balcom J IV, Rattner D, Warshaw A, Chang Y, Fernandez-del Castillo C. Ten-year experience with 733 pancreatic resections: changing indications, older patients, decreasing length of hospitalization. Arch Surg 2001; 136:391-8. [PMID 11296108]
31. Lillemoe K, Cameron J, Yeo C, Sohn T, Nakeeb A, Sauter P, et al. Pancreaticoduodenectomy. Does it have a role in the palliation of pancreatic cancer? Ann Surg 1996; 223:718-28. [PMID 8645045]